Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

T Cells Control Chemokine Secretion by Keratinocytes.

Rauschenberger T, Schmitt V, Azeem M, Klein-Hessling S, Murti K, Grän F, Goebeler M, Kerstan A, Klein M, Bopp T, Serfling E, Muhammad K.

Front Immunol. 2019 Aug 9;10:1917. doi: 10.3389/fimmu.2019.01917. eCollection 2019.

2.

Aberrant B-cell Subsets and Immunoglobulin Levels in Patients with Moderate-to-severe Psoriasis.

Kahlert K, Grän F, Muhammad K, Benoit S, Serfling E, Goebeler M, Kerstan A.

Acta Derm Venereol. 2019 Feb 1;99(2):226-227. doi: 10.2340/00015555-3069. No abstract available.

3.

The Transcription Factor NFATc1 Supports the Rejection of Heterotopic Heart Allografts.

Baur J, Otto C, Steger U, Klein-Hessling S, Muhammad K, Pusch T, Murti K, Wismer R, Germer CT, Klein I, Müller N, Serfling E, Avots A.

Front Immunol. 2018 Jun 12;9:1338. doi: 10.3389/fimmu.2018.01338. eCollection 2018.

4.

B cell development is critically dependent on NFATc1 activity.

Giampaolo S, Wójcik G, Klein-Hessling S, Serfling E, Patra AK.

Cell Mol Immunol. 2019 May;16(5):508-520. doi: 10.1038/s41423-018-0052-9. Epub 2018 Jun 15.

5.

NFAT-mediated defects in erythropoiesis cause anemia in Il2-/- mice.

Giampaolo S, Wójcik G, Klein-Hessling S, Serfling E, Patra AK.

Oncotarget. 2017 Dec 28;9(11):9632-9644. doi: 10.18632/oncotarget.23745. eCollection 2018 Feb 9.

6.

Induction of Short NFATc1/αA Isoform Interferes with Peripheral B Cell Differentiation.

Muhammad K, Rudolf R, Pham DAT, Klein-Hessling S, Takata K, Matsushita N, Ellenrieder V, Kondo E, Serfling E.

Front Immunol. 2018 Jan 24;9:32. doi: 10.3389/fimmu.2018.00032. eCollection 2018.

7.

Prolonged IKKβ Inhibition Improves Ongoing CTL Antitumor Responses by Incapacitating Regulatory T Cells.

Heuser C, Gotot J, Piotrowski EC, Philipp MS, Courrèges CJF, Otte MS, Guo L, Schmid-Burgk JL, Hornung V, Heine A, Knolle PA, Garbi N, Serfling E, Evaristo C, Thaiss F, Kurts C.

Cell Rep. 2017 Oct 17;21(3):578-586. doi: 10.1016/j.celrep.2017.09.082.

8.

Store-Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming.

Vaeth M, Maus M, Klein-Hessling S, Freinkman E, Yang J, Eckstein M, Cameron S, Turvey SE, Serfling E, Berberich-Siebelt F, Possemato R, Feske S.

Immunity. 2017 Oct 17;47(4):664-679.e6. doi: 10.1016/j.immuni.2017.09.003. Epub 2017 Oct 11.

9.

NFATc1 controls the cytotoxicity of CD8+ T cells.

Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, Qureischi M, Beilhack A, Vaeth M, Kummerow C, Backes C, Schoppmeyer R, Hahn U, Hoth M, Bopp T, Berberich-Siebelt F, Patra A, Avots A, Müller N, Schulze A, Serfling E.

Nat Commun. 2017 Sep 11;8(1):511. doi: 10.1038/s41467-017-00612-6.

10.

Interleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells.

Giampaolo S, Wójcik G, Serfling E, Patra AK.

Oncotarget. 2017 May 2;8(18):29625-29642. doi: 10.18632/oncotarget.16377.

11.

Corrigendum: NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.

Alrefai H, Muhammad K, Rudolf R, Pham DAT, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E.

Nat Commun. 2016 Aug 2;7:12421. doi: 10.1038/ncomms12421. No abstract available.

12.

A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia development.

Klein-Hessling S, Rudolf R, Muhammad K, Knobeloch KP, Maqbool MA, Cauchy P, Andrau JC, Avots A, Talora C, Ellenrieder V, Screpanti I, Serfling E, Patra AK.

Nat Commun. 2016 Jun 17;7:11841. doi: 10.1038/ncomms11841.

13.

NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.

Alrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E.

Nat Commun. 2016 May 25;7:11724. doi: 10.1038/ncomms11724. Erratum in: Nat Commun. 2016 Aug 02;7:12421.

14.

NFATc1 releases BCL6-dependent repression of CCR2 agonist expression in peritoneal macrophages from Saccharomyces cerevisiae infected mice.

Busch R, Murti K, Liu J, Patra AK, Muhammad K, Knobeloch KP, Lichtinger M, Bonifer C, Wörtge S, Waisman A, Reifenberg K, Ellenrieder V, Serfling E, Avots A.

Eur J Immunol. 2016 Mar;46(3):634-46. doi: 10.1002/eji.201545925. Epub 2016 Jan 8.

15.

Interleukin-2 critically regulates bone marrow erythropoiesis and prevents anemia development.

Chopra M, Langenhorst D, Beilhack A, Serfling E, Patra AK.

Eur J Immunol. 2015 Dec;45(12):3362-74. doi: 10.1002/eji.201545596. Epub 2015 Oct 15.

16.

NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms.

Dietz L, Frommer F, Vogel AL, Vaeth M, Serfling E, Waisman A, Buttmann M, Berberich-Siebelt F.

Eur J Immunol. 2015 May;45(5):1377-89. doi: 10.1002/eji.201444638. Epub 2015 Feb 19.

17.

NF-κB factors control the induction of NFATc1 in B lymphocytes.

Muhammad K, Alrefai H, Marienfeld R, Pham DA, Murti K, Patra AK, Avots A, Bukur V, Sahin U, Kondo E, Klein-Hessling S, Serfling E.

Eur J Immunol. 2014 Nov;44(11):3392-402. doi: 10.1002/eji.201444756. Epub 2014 Sep 26.

18.

Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression.

Vaeth M, Müller G, Stauss D, Dietz L, Klein-Hessling S, Serfling E, Lipp M, Berberich I, Berberich-Siebelt F.

J Exp Med. 2014 Mar 10;211(3):545-61. doi: 10.1084/jem.20130604. Epub 2014 Mar 3.

19.

Architecture and expression of the nfatc1 gene in lymphocytes.

Rudolf R, Busch R, Patra AK, Muhammad K, Avots A, Andrau JC, Klein-Hessling S, Serfling E.

Front Immunol. 2014 Feb 3;5:21. doi: 10.3389/fimmu.2014.00021. eCollection 2014. Review.

20.

NFATc1 induction in peripheral T and B lymphocytes.

Hock M, Vaeth M, Rudolf R, Patra AK, Pham DA, Muhammad K, Pusch T, Bopp T, Schmitt E, Rost R, Berberich-Siebelt F, Tyrsin D, Chuvpilo S, Avots A, Serfling E, Klein-Hessling S.

J Immunol. 2013 Mar 1;190(5):2345-53. doi: 10.4049/jimmunol.1201591. Epub 2013 Jan 30.

21.

Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB.

Mueller K, Quandt J, Marienfeld RB, Weihrich P, Fiedler K, Claussnitzer M, Laumen H, Vaeth M, Berberich-Siebelt F, Serfling E, Wirth T, Brunner C.

Nucleic Acids Res. 2013 Feb 1;41(4):2138-54. doi: 10.1093/nar/gks1349. Epub 2013 Jan 4.

22.

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Benkert TF, Dietz L, Hartmann EM, Leich E, Rosenwald A, Serfling E, Buttmann M, Berberich-Siebelt F.

PLoS One. 2012;7(12):e52208. doi: 10.1371/journal.pone.0052208. Epub 2012 Dec 20.

23.

An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development.

Patra AK, Avots A, Zahedi RP, Schüler T, Sickmann A, Bommhardt U, Serfling E.

Nat Immunol. 2013 Feb;14(2):127-35. doi: 10.1038/ni.2507. Epub 2012 Dec 23.

PMID:
23263556
24.

Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells.

Vaeth M, Schliesser U, Müller G, Reissig S, Satoh K, Tuettenberg A, Jonuleit H, Waisman A, Müller MR, Serfling E, Sawitzki BS, Berberich-Siebelt F.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16258-63. doi: 10.1073/pnas.1203870109. Epub 2012 Sep 18.

25.

NFATc1/αA: The other Face of NFAT Factors in Lymphocytes.

Serfling E, Avots A, Klein-Hessling S, Rudolf R, Vaeth M, Berberich-Siebelt F.

Cell Commun Signal. 2012 Jul 5;10(1):16. doi: 10.1186/1478-811X-10-16.

26.

Cyclic AMP underpins suppression by regulatory T cells.

Bodor J, Bopp T, Vaeth M, Klein M, Serfling E, Hünig T, Becker C, Schild H, Schmitt E.

Eur J Immunol. 2012 Jun;42(6):1375-84. doi: 10.1002/eji.201141578. Review.

27.

NFATc1 affects mouse splenic B cell function by controlling the calcineurin--NFAT signaling network.

Bhattacharyya S, Deb J, Patra AK, Thuy Pham DA, Chen W, Vaeth M, Berberich-Siebelt F, Klein-Hessling S, Lamperti ED, Reifenberg K, Jellusova J, Schweizer A, Nitschke L, Leich E, Rosenwald A, Brunner C, Engelmann S, Bommhardt U, Avots A, Müller MR, Kondo E, Serfling E.

J Exp Med. 2011 Apr 11;208(4):823-39. doi: 10.1084/jem.20100945. Epub 2011 Apr 4.

28.

Transcriptional programming in the immune system: report on the International Workshop of the Transregio TR52, November 17-20, 2010 in Würzburg, Germany.

Berberich-Siebelt F, Avots A, Serfling E.

Eur J Immunol. 2011 Apr;41(4):885-8. doi: 10.1002/eji.201190016. No abstract available.

29.

Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1).

Vaeth M, Gogishvili T, Bopp T, Klein M, Berberich-Siebelt F, Gattenloehner S, Avots A, Sparwasser T, Grebe N, Schmitt E, Hünig T, Serfling E, Bodor J.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2480-5. doi: 10.1073/pnas.1009463108. Epub 2011 Jan 24.

30.

Signal transduction--receptors, mediators, and genes.

Entschladen F, Lindquist JA, Serfling E, Thiel G, Kieser A, Giehl K, Ehrhardt C, Feller SM, Ullrich O, Schaper F, Janssen O, Hass R, Friedrich K.

Sci Signal. 2009 Mar 24;2(63):mr3. doi: 10.1126/scisignal.263mr3. Review.

PMID:
19318619
31.

Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development.

Gattenlöhner S, Stühmer T, Leich E, Reinhard M, Etschmann B, Völker HU, Rosenwald A, Serfling E, Bargou RC, Ertl G, Einsele H, Müller-Hermelink HK.

Am J Pathol. 2009 Apr;174(4):1160-71. doi: 10.2353/ajpath.2009.080647. Epub 2009 Feb 26.

32.

Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase.

Nayak A, Glöckner-Pagel J, Vaeth M, Schumann JE, Buttmann M, Bopp T, Schmitt E, Serfling E, Berberich-Siebelt F.

J Biol Chem. 2009 Apr 17;284(16):10935-46. doi: 10.1074/jbc.M900465200. Epub 2009 Feb 14.

33.

Signal transduction in the footsteps of goethe and schiller.

Friedrich K, Lindquist JA, Entschladen F, Serfling E, Thiel G, Kieser A, Giehl K, Ehrhardt C, Feller SM, Ullrich O, Schaper F, Janssen O, Hass R.

Cell Commun Signal. 2009 Feb 4;7:2. doi: 10.1186/1478-811X-7-2.

34.

Cyclic AMP-induced chromatin changes support the NFATc-mediated recruitment of GATA-3 to the interleukin 5 promoter.

Klein-Hessling S, Bopp T, Jha MK, Schmidt A, Miyatake S, Schmitt E, Serfling E.

J Biol Chem. 2008 Nov 7;283(45):31030-7. doi: 10.1074/jbc.M805929200. Epub 2008 Sep 4.

35.

Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F.

Gattenlohner S, Serfling E, Einsele H, Müller-Hermelink HK.

Leukemia. 2009 Jan;23(1):196-9. doi: 10.1038/leu.2008.168. Epub 2008 Jun 26. No abstract available.

PMID:
18580953
36.

Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.

Akimzhanov A, Krenacs L, Schlegel T, Klein-Hessling S, Bagdi E, Stelkovics E, Kondo E, Chuvpilo S, Wilke P, Avots A, Gattenlöhner S, Müller-Hermelink HK, Palmetshofer A, Serfling E.

Am J Pathol. 2008 Jan;172(1):215-24. Epub 2007 Dec 21.

37.

Inhibition of calcineurin-NFAT signaling by the pyrazolopyrimidine compound NCI3.

Sieber M, Karanik M, Brandt C, Blex C, Podtschaske M, Erdmann F, Rost R, Serfling E, Liebscher J, Pätzel M, Radbruch A, Fischer G, Baumgrass R.

Eur J Immunol. 2007 Sep;37(9):2617-26.

38.

NFAT in lymphocytes: a factor for all events?

Serfling E, Berberich-Siebelt F, Avots A.

Sci STKE. 2007 Aug 7;2007(398):pe42. Review.

PMID:
17684296
39.

A costimulation-initiated signaling pathway regulates NFATc1 transcription in T lymphocytes.

Nurieva RI, Chuvpilo S, Wieder ED, Elkon KB, Locksley R, Serfling E, Dong C.

J Immunol. 2007 Jul 15;179(2):1096-103.

40.

Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression.

Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E.

J Exp Med. 2007 Jun 11;204(6):1303-10. Epub 2007 May 14.

41.

Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression.

Gattenloehner S, Chuvpilo S, Langebrake C, Reinhardt D, Müller-Hermelink HK, Serfling E, Vincent A, Marx A.

Blood. 2007 Sep 15;110(6):2027-33. Epub 2007 Apr 12.

42.

Epigenetic control of the foxp3 locus in regulatory T cells.

Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J.

PLoS Biol. 2007 Feb;5(2):e38.

43.

Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells.

Buttmann M, Berberich-Siebelt F, Serfling E, Rieckmann P.

J Vasc Res. 2007;44(1):51-60. Epub 2006 Dec 13.

PMID:
17167270
44.

Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines.

Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Tertilt C, Bopp T, Heib V, Becker M, Taube C, Schild H, Schmitt E, Stassen M.

J Immunol. 2006 Nov 15;177(10):6667-74.

45.

NFAT transcription factors in control of peripheral T cell tolerance.

Serfling E, Klein-Hessling S, Palmetshofer A, Bopp T, Stassen M, Schmitt E.

Eur J Immunol. 2006 Nov;36(11):2837-43. Review.

46.

PKB rescues calcineurin/NFAT-induced arrest of Rag expression and pre-T cell differentiation.

Patra AK, Drewes T, Engelmann S, Chuvpilo S, Kishi H, Hünig T, Serfling E, Bommhardt UH.

J Immunol. 2006 Oct 1;177(7):4567-76.

47.

NFATc1 autoregulation: a crucial step for cell-fate determination.

Serfling E, Chuvpilo S, Liu J, Höfer T, Palmetshofer A.

Trends Immunol. 2006 Oct;27(10):461-9. Epub 2006 Aug 22.

PMID:
16931157
48.

p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1.

Stassen M, Klein M, Becker M, Bopp T, Neudörfl C, Richter C, Heib V, Klein-Hessling S, Serfling E, Schild H, Schmitt E.

Mol Immunol. 2007 Feb;44(5):926-33. Epub 2006 May 2.

PMID:
16650898
49.

SUMOylation interferes with CCAAT/enhancer-binding protein beta-mediated c-myc repression, but not IL-4 activation in T cells.

Berberich-Siebelt F, Berberich I, Andrulis M, Santner-Nanan B, Jha MK, Klein-Hessling S, Schimpl A, Serfling E.

J Immunol. 2006 Apr 15;176(8):4843-51.

50.

Autoamplification of NFATc1 expression determines its essential role in bone homeostasis.

Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H.

J Exp Med. 2005 Nov 7;202(9):1261-9.

Supplemental Content

Loading ...
Support Center